<DOC>
	<DOCNO>NCT00554775</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-ray kill tumor cell . Erlotinib may stop growth tumor cell block enzymes need cell growth . Erlotinib may also make tumor cell sensitive radiation therapy . It yet know whether give whole-brain radiation therapy together erlotinib effective whole-brain radiation therapy alone treat patient non-small cell lung cancer brain metastasis . PURPOSE : This randomized phase II trial study whole-brain radiation therapy erlotinib see well work compare whole-brain radiation therapy alone treat patient advance non-small cell lung cancer brain metastasis .</brief_summary>
	<brief_title>WBRT &amp; Erlotinib Advanced NSCLC Brain Metastases</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect whole-brain radiotherapy ( WBRT ) erlotinib hydrochloride v WBRT alone neurological progression-free survival 2 month patient advance non-small cell lung cancer multiple brain metastasis . Secondary - Compare toxicity regimen . - Compare response rate patient . - Compare quality life patient . - Compare change performance status patient . - Compare steroid dosing patient . - Compare sit progression ( cranial extracranial ) patient . OUTLINE : This multicenter study . Patients stratify presence extracranial metastasis ( yes v ) , RTOG recursive partition analysis ( RPA ) score ( I vs II ) treatment center . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo whole-brain radiotherapy ( WBRT ) daily 5 day . Patients also receive oral erlotinib hydrochloride daily 24 month . - Arm II : Patients undergo WBRT arm I . Patients also receive oral placebo daily 24 month . Quality life assess baseline , monthly 12 month , 18 24 month . After completion study therapy , patient follow every 1-2 month . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced nonsmall cell lung cancer ( NSCLC ) meet 1 follow criterion : Newly diagnose multiple brain metastasis suitable firstline chemotherapy Relapsed NSCLC newly diagnose multiple brain metastasis Relapsed secondline chemotherapy newly diagnose multiple brain metastasis NOTE : *Biopsy brain metastasis require Diagnosis brain metastasis must confirm contrast CT scan MRI within past 4 week Symptoms attributable brain metastasis Patients undergone craniotomy incomplete resection eligible Clinician certain wholebrain radiotherapy ( WBRT ) beneficial No evidence solitary brain metastasis MRI treat surgical resection , radiosurgery , stereotactic radiotherapy No 3 site ( organ system ) extracranial metastases No liver metastases PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % RTOG recursive partitioning analysis ( RPA ) class I II Serum bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 2 time ULN ( &lt; 5 time ULN liver metastasis present ) Creatinine &lt; 5 time ULN Able take oral medication Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Caretaker able willing participate study Patient caretaker access telephone willing respond telephone interview No prior concurrent malignant disease likely interfere study treatment comparison No evidence significant laboratory find concurrent uncontrolled medical illness , opinion investigator , would interfere study treatment result comparison render patient high risk treatment complication include , limited , follow : Severe uncontrolled infection Unstable angina Myocardial infarction within past month Uncontrolled inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) Acute renal failure PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 28 day since prior chemotherapy ( relapsed patient originally treat chemotherapy ) No prior cranial radiotherapy No prior anticancer EGFR therapy ( e.g. , erlotinib , gefitinib , cetuximab ) No prior treatment brain metastasis ( e.g. , radiosurgery , radiotherapy , chemotherapy ) Prior radiotherapy primary tumor and/or systemic treatment metastatic site disease allow No concurrent cyclooxygenase2 ( COX2 ) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>